Neurology 1999;52:1239
© 1999 American Academy of Neurology
Articles
Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
F. Deisenhammer, MD,
M. Reindl, PhD,
J. Harvey, PhD,
T. Gasse, MD,
E. Dilitz, MD and
T. Berger, MD
From the Department of Neurology (Drs. Deisenhammer, Reindl, Gasse, Dilitz, and Berger), University of Innsbruck, Austria; and Chiron Diagnostics (Dr. Harvey), Alameda, CA.
Address correspondence and reprint requests to Dr. Florian Deisenhammer, Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
BACKGROUND: Neutralizing antibodies (NAB) to interferon beta (IFNß) occur in about one-third of MS patients treated with IFNß-1b and there is an association with a loss of clinical and MRI efficacy. However, there are no data regarding the bioavailability of IFNß-1b in patients with and without NAB.
METHODS: The authors measured MxA in whole blood by ELISA, and serum-binding antibodies (SBA) by Western blot and ELISA in 134 samples of MS patients on IFNß-1b and 54 control subjects, and correlated the MxA levels and SBA titers with the NAB titer.
RESULTS: In the IFNß group 84 samples were NAB negative, 21 were NAB positive (i.e., titer of  20), and 29 had detectable NAB (i.e., titer between 10 and 20). The median MxA concentration in NAB-negative patients was 4.09 ng/105 peripheral blood leukocytes (PBL), 2.37 ng/105 PBL in samples with detectable NAB, 0.36 ng/105 PBL in NAB-positive samples, and 0.27 ng/105 PBL in control subjects. There was no significant difference between NAB-positive samples and control subjects, otherwise the groups differed significantly from each other. SBA occurred in 49% of NAB-negative samples, in 79% of samples with detectable NAB, and in all NAB-positive samples. With regard to the SBA titer, all groups differed significantly from each other. In none of the control samples were SBA detected.
CONCLUSION: The conversion of SBA into NAB depends to some degree on the SBA titer, but other mechanisms may be involved. Once NAB have developed, the bioavailability of IFNß as measured by MxA is completely inhibited.
This article has been cited by other articles:
|
|
|
|
 
A. R. Pachner, D. Cadavid, L. Wolansky, and J. Skurnick
Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study
Neurology,
November 3, 2009;
73(18):
1485 - 1492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Pachner, J. D. Warth, A. Pace, S. Goelz, and On behalf of the INSIGHT investigators
Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study
Neurology,
November 3, 2009;
73(18):
1493 - 1500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hesse, F. Sellebjerg, and P. S. Sorensen
Absence of MxA induction by interferon {beta} in patients with MS reflects complete loss of bioactivity
Neurology,
August 4, 2009;
73(5):
372 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Millonig, D Rudzki, M Holzl, R Ehling, C Gneiss, B Kunz, T Berger, M Reindl, and F Deisenhammer
High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study
Multiple Sclerosis,
August 1, 2009;
15(8):
977 - 983.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Ravnborg, K Bendtzen, O Christensen, P. Jensen, D Hesse, M. Tovey, and P. Sorensen
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis
Multiple Sclerosis,
March 1, 2009;
15(3):
323 - 328.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. van der Voort, A Kok, A Visser, C. Oudejans, M Caldano, F Gilli, A Bertolotto, C. Polman, and J Killestein
Interferon-{beta} bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice
Multiple Sclerosis,
February 1, 2009;
15(2):
212 - 218.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Gilli, P. Valentino, M. Caldano, L. Granieri, M. Capobianco, S. Malucchi, A. Sala, F. Marnetto, and A. Bertolotto
Expression and regulation of IFN{alpha}/{beta} receptor in IFN{beta}-treated patients with multiple sclerosis
Neurology,
December 9, 2008;
71(24):
1940 - 1947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Soelberg Sorensen
Review: Neutralizing antibodies against interferon-beta
Therapeutic Advances in Neurological Disorders,
September 1, 2008;
1(2):
125 - 141.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen
Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies?
Multiple Sclerosis,
July 1, 2008;
14(6):
837 - 842.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C Gneiss, M Brugger, A Millonig, A Fogdell-Hahn, D Rudzki, J Hillert, T Berger, M Reindl, and F Deisenhammer
Comparative study of four different assays for the detection of binding antibodies against interferon-{beta}
Multiple Sclerosis,
July 1, 2008;
14(6):
830 - 836.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto
Predictive markers for response to interferon therapy in patients with multiple sclerosis
Neurology,
March 25, 2008;
70(13_Part_2):
1119 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Sominanda, J Hillert, and A Fogdell-Hahn
In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
J. Neurol. Neurosurg. Psychiatry,
January 1, 2008;
79(1):
57 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic
Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study
Multiple Sclerosis,
November 1, 2007;
13(9):
1127 - 1137.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A Farrell and G. Giovannoni
Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis
Multiple Sclerosis,
June 1, 2007;
13(5):
567 - 577.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Deisenhammer
Neutralizing antibody (NAb) assays in multiple sclerosis patients receiving interferon-{beta} therapy
Multiple Sclerosis,
May 1, 2007;
13(1_suppl):
44 - 48.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F Gilli, F Hoffmann, A Sala, F Marnetto, M Caldano, P Valentino, L Kappos, A Bertolotto, and R L. Lindberg
Qualitative and quantitative analysis of antibody response against IFN{beta} in patients with multiple sclerosis
Multiple Sclerosis,
November 1, 2006;
12(6):
738 - 746.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, and A Bertolotto
Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1
Multiple Sclerosis,
February 1, 2006;
12(1):
47 - 57.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Kappos, M. Clanet, M. Sandberg-Wollheim, E. W. Radue, H. P. Hartung, R. Hohlfeld, J. Xu, D. Bennett, A. Sandrock, S. Goelz, et al.
Neutralizing antibodies and efficacy of interferon {beta}-1a: A 4-year controlled study
Neurology,
July 12, 2005;
65(1):
40 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil
Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS
Neurology,
July 12, 2005;
65(1):
48 - 55.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
Neurology,
July 12, 2005;
65(1):
33 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, and F Deisenhammer
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity
Multiple Sclerosis,
October 1, 2004;
10(5):
507 - 510.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G Giovannoni
Is it time to consider rationalising IFN-{beta} treatment in individuals with multiple sclerosis?
J. Neurol. Neurosurg. Psychiatry,
September 1, 2004;
75(9):
1234 - 1234.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Bertolotto, A Sala, S Malucchi, F Marnetto, M Caldano, A Di Sapio, M Capobianco, and F Gilli
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies
J. Neurol. Neurosurg. Psychiatry,
September 1, 2004;
75(9):
1294 - 1299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. P. Yeung, J. Chang, J. Miller, C. Barnett, M. Stickler, and F. A. Harding
Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-{beta} Does Not Result in an In Vivo Response Directed at the Subdominant Epitope
J. Immunol.,
June 1, 2004;
172(11):
6658 - 6665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert
Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs
Brain,
February 1, 2004;
127(2):
259 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Pachner
An improved ELISA for screening for neutralizing anti-IFN-{beta} antibodies in MS patients
Neurology,
November 25, 2003;
61(10):
1444 - 1446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Pachner, J. Oger, and J. Palace
The measurement of antibodies binding to IFN{beta} in MS patients treated with IFN{beta}
Neurology,
November 11, 2003;
61(90095):
S18 - 20.
[Full Text]
|
|
|
|
|
|
|
A. R. Pachner, A. Bertolotto, and F. Deisenhammer
Measurement of MxA mRNA or protein as a biomarker of IFN{beta} bioactivity: Detection of antibody-mediated decreased bioactivity (ADB)
Neurology,
November 11, 2003;
61(90095):
S24 - 26.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. A. Rudick
Biologic impact of interferon antibodies, and complexities in assessing their clinical significance
Neurology,
November 11, 2003;
61(90095):
S31 - 34.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R. L.P. Lindberg, R. Bottero, et al.
Persistent neutralizing antibodies abolish the interferon {beta} bioavailability in MS patients
Neurology,
February 25, 2003;
60(4):
634 - 639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Kob, J Harvey, F Schautzer, S Kascha, D Bibl, R Egg, M Reindl, T Berger, and F Deisenhammer
A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta
Multiple Sclerosis,
February 1, 2003;
9(1):
32 - 35.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Scagnolari, M. Casato, F. Bellomi, F. De Pisa, O. Turriziani, R. Coviello, M. R. Pirro, F. Dianzani, and G. Antonelli
Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia
Clin. Vaccine Immunol.,
January 1, 2003;
10(1):
70 - 77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Giovannoni, F E Munschauer 3rd, and F Deisenhammer
Neutralising antibodies to interferon beta during the treatment of multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
November 1, 2002;
73(5):
465 - 469.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Bertolotto, S Malucchi, A Sala, G Orefice, P B Carrieri, M Capobianco, E Milano, F Melis, and M T Giordana
Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory
J. Neurol. Neurosurg. Psychiatry,
August 1, 2002;
73(2):
148 - 153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Vallittu, M. Halminen, J. Peltoniemi, J. Ilonen, I. Julkunen, A. Salmi, J.-P. Eralinna, and the Finnish Beta-Interferon Study Group
Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients
Neurology,
June 25, 2002;
58(12):
1786 - 1790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Cook, J. R. Quinless, A. Jotkowitz, and P. Beaton
Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients
Neurology,
September 25, 2001;
57(6):
1080 - 1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Pachner
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol,
August 1, 2001;
58(8):
1299 - 1300.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. C. Q. Zang, D. Yang, J. Hong, M. V. Tejada-Simon, V. M. Rivera, and J. Z. Zhang
Immunoregulation and blocking antibodies induced by interferon beta treatment in MS
Neurology,
August 8, 2000;
55(3):
397 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Deisenhammer, I. Mayringer, J. Harvey, E. Dilitz, T. Gasse, D. Stadlbauer, M. Reindl, and T. Berger
A comparative study of the relative bioavailability of different interferon beta preparations
Neurology,
June 13, 2000;
54(11):
2055 - 2060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kracke, P. von Wussow, A. N. Al-Masri, G. Dalley, A. Windhagen, and F. Heidenreich
Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS
Neurology,
January 11, 2000;
54(1):
193 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
